Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:2009:730739.
doi: 10.1155/2009/730739. Epub 2009 Nov 1.

Expression of Semaphorin 3F and Its Receptors in Epithelial Ovarian Cancer, Fallopian Tubes, and Secondary Müllerian Tissues

Christina D Drenberg  1 , Sandra Livingston, Ren Chen, Patricia A Kruk, Santo V Nicosia
Affiliations

Expression of Semaphorin 3F and Its Receptors in Epithelial Ovarian Cancer, Fallopian Tubes, and Secondary Müllerian Tissues

Christina D Drenberg et al. Obstet Gynecol Int. 2009.

Abstract

While semaphorins and their receptors appear to play a role in tumor carcinogenesis, little is known about the role of semaphorin 3F (S3F) in epithelial ovarian cancer (EOC) development. Therefore, we sought to determine the clinical relationship between S3F and its receptors, neuropilin-2 (NP-2) and neuropilin-1 (NP-1) with EOC progression. We analyzed the immunohistological expression of S3F, NP-2, and NP-1 in clinical specimens of normal ovaries (N), benign cystadenomas (Cy), well-differentiated adenocarcinomas (WD), poorly-differentiated adenocarcinomas (PD), inclusion cysts (IC), paraovarian cysts (PC), and fallopian tubes (FT). Tissue sections were evaluated for staining intensity and percentage of immunoreactive epithelia. We found that expression of S3F and NP-2 decreased while NP-1 expression increased with EOC progression. Interestingly, we also found elevated expression of S3F, NP-2, and NP-1 in epithelia of ICs, PCs, and FT. Our findings indicate that loss or deregulation of semaphorin signaling may play an important role in EOC development.

PubMed Disclaimer

Figures

Figure 1
Figure 1
S3F expression decreases while NP-1 increases with epithelial ovarian cancer progression. Representative illustrations of immunohistochemical staining of normal (N), serous cystadenoma (Cy), well-differentiated (WD) and poorly differentiated (PD) serous adenocarcinomas) for S3F, NP-2, and NP-1. Placental tissue was used for positive control (C) and arrow indicates expression of S3F by endothelial cells. Primary antibodies were replaced with non-immune serum in negative control sections (inset). Original magnification: 400×.
Figure 2
Figure 2
Graphical depiction of S3F, NP-2, and NP-1 expression with epithelial ovarian cancer progression. Immunohistochemically stained sections of normal (N), serous cystadenomas (Cy), well-differentiated (WD) and poorly differentiated (PD) serous adenocarcinomas were evaluated for expression of S3f, NP-2 and NP-1 and scored as negative, weak, moderate, or strong as described in Materials and Methods.
Figure 3
Figure 3
NP-2 expression occurs in distinct clusters of tumor cells. Representative illustration of NP-2 expression in well-differentiated serous adenocarcinoma (WD). Original magnification is 100× and inset is 200×.
Figure 4
Figure 4
S3F expression is elevated in inclusion cysts, paraovarian cysts, and fallopian tubes. Representative illustrations of immunohistochemical staining of normal ovary (N), inclusion cyst (IC), paraovarian cyst (PC), and fallopian tube (FT) for S3F, NP-2, and NP-1. Original magnification is 400×.
Figure 5
Figure 5
Graphical depiction of S3F, NP-2, and NP-1 expression in inclusion cysts, paraovarian cysts, and fallopian tubes compared to normal ovaries. Immunohistochemically stained sections of normal ovary (N), inclusion cysts (IC), paraovarian cysts (PC) and fallopian tubes (FT) were evaluated for staining intensity and designated as negative, weak, moderate, or strong following staining with antibodies directed against S3F, NP-2, and NP-1.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA: A Cancer Journal for Clinicians. 2009;59:225–249. - PubMed
    1. Williams TI, Toups KL, Saggese DA, Kalli KR, Cliby WA, Muddiman DC. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. Journal of Proteome Research. 2007;6:2936–2962. - PubMed
    1. Piek JMJ, Kenemans P, Verheijen RHM. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. American Journal of Obstetrics and Gynecology. 2004;191(3):718–732. - PubMed
    1. Dubeau L. The cell of origin of ovarian epithelial tumours. The Lancet Oncology. 2008;9(12):1191–1197. - PMC - PubMed
    1. Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nature Reviews Cancer. 2008;8(8):632–645. - PubMed

LinkOut - more resources